Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer

Yuming Jiang(Wake Forest University), Ruijiang Li(Peking University), Qiang Yuan(Nanfang Hospital), Zhiwei Zhou(Sun Yat-sen University), G. Li(Key Laboratory of Guangdong Province), Weibin Huang(Xiamen University), H. Wang(Stanford University), Chuanxiang Chen(Jiangsu University of Science and Technology), Shuhua Xi(Liaoning University), Yue Hu(Innsbruck Medical University), Jia Wu(The University of Texas MD Anderson Cancer Center), Yadan Xu(Nanfang Hospital), Ting Li(Sun Yat-sen University)
Annals of Oncology
March 30, 2020
10.1016/j.annonc.2020.03.295
Cited by 175

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer
|JAMA Oncology|2017|600
A pathology foundation model for cancer diagnosis and prognosis prediction
|Nature|2024|445
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Machine Learning in Radiation Oncology
|Unknown|2015|277